Axon Enterprise (NASDAQ:AXON) Stock Rating Reaffirmed by JMP Securities

Axon Enterprise (NASDAQ:AXON)‘s stock had its “market outperform” rating restated by equities researchers at JMP Securities in a report issued on Tuesday, Benzinga reports. They presently have a $375.00 price objective on the biotechnology company’s stock. JMP Securities’ price target points to a potential upside of 20.25% from the stock’s current price.

Several other research firms have also weighed in on AXON. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. TheStreet lowered Axon Enterprise from a “b” rating to a “c+” rating in a research note on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a research note on Tuesday. Morgan Stanley increased their price objective on Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday, April 26th. Finally, The Goldman Sachs Group increased their price objective on Axon Enterprise from $297.00 to $339.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $333.08.

Axon Enterprise Stock Down 0.3 %

Axon Enterprise stock opened at $311.86 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 3.00. The firm has a market capitalization of $23.53 billion, a price-to-earnings ratio of 135.59 and a beta of 0.91. Axon Enterprise has a fifty-two week low of $175.37 and a fifty-two week high of $329.87. The stock’s fifty day moving average is $310.82 and its two-hundred day moving average is $267.44.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Monday, May 6th. The biotechnology company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. Axon Enterprise’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.51 earnings per share. Analysts predict that Axon Enterprise will post 2.44 EPS for the current fiscal year.

Institutional Trading of Axon Enterprise

A number of hedge funds have recently added to or reduced their stakes in AXON. Norges Bank acquired a new stake in Axon Enterprise in the 4th quarter worth about $195,406,000. Sands Capital Management LLC raised its holdings in shares of Axon Enterprise by 31.1% in the 3rd quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company’s stock worth $519,823,000 after purchasing an additional 619,179 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of Axon Enterprise by 184.3% in the 3rd quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock worth $138,535,000 after purchasing an additional 451,350 shares during the period. Motley Fool Asset Management LLC raised its holdings in shares of Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after purchasing an additional 346,838 shares during the period. Finally, Polar Capital Holdings Plc raised its holdings in shares of Axon Enterprise by 292.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 265,464 shares of the biotechnology company’s stock worth $52,825,000 after purchasing an additional 197,746 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.